Gamma-ketoaldehyde scavengers for alcoholic liver disease
Award amount
$151,587Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MTI Biotech Incorporated
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- N5NDNJL8QGA1
- Solicitation number
- PA14-071
- Topic code
- NIAAA
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- 2-HOBA for Treatment of Pulmonary Hypertension
- 2-HOBA for Treatment of Pulmonary Hypertension
- Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis
- Hydroxybenzylamine for the prevention of Alzheimer s disease Initial evaluation in humans
- Nutritional Intervention for Age Related Muscular Function and Strength Losses
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
- DEVELOPMENT OF NOVEL PDE4B INHIBITORS TO TREAT ALCOHOL USE DISORDER (SBIR PHASE II)
- SBIR PHASE I - WEARABLE BIOSENSOR THAT QUANTIFIES BLOOD ALCOHOL CONCENTRATION IN REAL TIME
- THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.
- Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
Research funding history
17 SBIR/STTR records share this UEI (1995–2023). Reported award amounts total $8,355,488. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Agriculture, National Science Foundation